Axon Enterprise, Inc $AXON Shares Acquired by Roundview Capital LLC

Roundview Capital LLC lifted its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 25.8% in the second quarter, Holdings Channel reports. The institutional investor owned 1,461 shares of the biotechnology company’s stock after acquiring an additional 300 shares during the quarter. Roundview Capital LLC’s holdings in Axon Enterprise were worth $1,210,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. TCI Wealth Advisors Inc. acquired a new stake in shares of Axon Enterprise during the 2nd quarter worth approximately $214,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Axon Enterprise during the 1st quarter worth approximately $1,110,000. Quotient Wealth Partners LLC purchased a new position in shares of Axon Enterprise during the 1st quarter worth approximately $438,000. CX Institutional purchased a new position in shares of Axon Enterprise during the 1st quarter worth approximately $115,000. Finally, GAMMA Investing LLC boosted its position in shares of Axon Enterprise by 11.8% during the 1st quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company’s stock worth $765,000 after purchasing an additional 154 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 15,919 shares of Axon Enterprise stock in a transaction on Friday, August 15th. The shares were sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the sale, the president directly owned 238,379 shares in the company, valued at $177,892,712.54. This trade represents a 6.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction on Thursday, September 11th. The stock was sold at an average price of $752.54, for a total transaction of $75,254.00. Following the sale, the director owned 1,416 shares in the company, valued at $1,065,596.64. This represents a 6.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,932 shares of company stock worth $37,978,216. 5.70% of the stock is currently owned by company insiders.

Axon Enterprise Price Performance

Axon Enterprise stock opened at $714.60 on Wednesday. The stock has a market cap of $56.10 billion, a P/E ratio of 176.44, a price-to-earnings-growth ratio of 28.02 and a beta of 1.41. The company has a fifty day simple moving average of $757.21 and a 200-day simple moving average of $710.53. Axon Enterprise, Inc has a 12-month low of $420.49 and a 12-month high of $885.91. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58. The business had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The company’s revenue for the quarter was up 32.6% on a year-over-year basis. During the same period in the previous year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. Equities analysts expect that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Analysts Set New Price Targets

AXON has been the subject of a number of research analyst reports. Northland Securities set a $800.00 price objective on shares of Axon Enterprise in a research report on Tuesday, August 5th. JMP Securities reaffirmed a “market outperform” rating and set a $825.00 price objective on shares of Axon Enterprise in a research report on Monday, September 29th. Morgan Stanley set a $885.00 price objective on shares of Axon Enterprise and gave the stock an “overweight” rating in a research report on Friday, July 11th. UBS Group reaffirmed a “neutral” rating and set a $840.00 price objective (up previously from $820.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Finally, Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price target for the company in a research report on Tuesday, August 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $841.64.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.